Nobuaki Suzuki

Dr. Nobuaki Suzuki


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
TKTakashi Kubo
Takashi Kubo
TATakashi Akasaka
Takashi Akasaka
JSJunya Shite
Junya Shite
TSTakahiko Suzuki
Takahiko Suzuki
SUShiro Uemura
Shiro Uemura
SZShaosong Zhang
Shaosong Zhang

1 May 2010 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
GGGiulio Guagliumi
Giulio Guagliumi
GMGiuseppe Musumeci
Giuseppe Musumeci
VSVasile Sirbu
Vasile Sirbu
HBHiram G. Bezerra
Hiram G. Bezerra
NSNobuaki Suzuki
Nobuaki Suzuki
MCMarco A. Costa
Marco A. Costa

25 January 2011 in Circulation
Verified
Journal Article
Open access
PDF file
GGGiulio Guagliumi
Giulio Guagliumi
MCMarco A. Costa
Marco A. Costa
VSVasile Sirbu
Vasile Sirbu
GMGiuseppe Musumeci
Giuseppe Musumeci
HBHiram G. Bezerra
Hiram G. Bezerra
GSGregg W. Stone
Gregg W. Stone
Background—: The safety of drug-eluting stents in ST-segment elevation myocardial infarction (STEMI) continues to be debated. Pathological studies have demonstrated an association between uncovered struts and subsequent stent thrombosis. Optical coherence tomography can detect stent strut coverage in vivo on a micron-scale level. We therefore used optical coherence tomography to examine strut coverage in patients with STEMI treated with paclitaxel-eluting stents (PES) and bare metal stents (BMS). Methods and Results—: In the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, patients with STEMI were randomized 3:1 to PES or BMS implantation. In a formal substudy, optical coherence tomography at 13 months was performed in 118 consecutive randomized patients (89 PES, 29 BMS) in whom 188 stents were assessed (146 PES and 42 BMS). A total of 44 139 stent struts were analyzed by an independent core laboratory blinded to stent assignment. The primary prespecified end point, the percentage of uncovered stent struts per lesion at follow-up, was 1.1±2.5% in BMS lesions versus 5.7±7.0% in PES lesions ( P <0.0001). Malapposed struts were observed in 0.1±0.2% of BMS lesions versus 0.9±2.1% of PES lesions ( P =0.0003). Percentage net volume obstruction was 36.0±15.4% with BMS and 19.2±11.3% with PES ( P <0.0001). Conclusions—: In patients with STEMI undergoing primary percutaneous coronary intervention, implantation of PES as compared with BMS significantly reduces neointimal hyperplasia but results in higher rates of uncovered and malapposed stent struts as assessed by optical coherence tomography at 13-month follow-up. Further studies are required to determine the clinical significance of these findings. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00433966.

31 May 2011 in Circulation
Verified
Journal Article
Closed access
MIMasao Imai
Masao Imai
KKKazushige Kadota
Kazushige Kadota
TGTsuyoshi Goto
Tsuyoshi Goto
SFSatoki Fujii
Satoki Fujii
HYHiroyuki Yamamoto
Hiroyuki Yamamoto
KMKazuaki Mitsudo
Kazuaki Mitsudo
Background—: We have noted abnormal angiographic findings—at the sites of drug-eluting stent implantation, suggesting contrast staining outside the stent struts—that do not fulfill the classic definition of coronary artery aneurysm. We propose a new term, peri-stent contrast staining (PSS), for these abnormal angiographic findings and assess their incidence, risk factors, and clinical sequelae. Methods and Results—: Peri-stent contrast staining was defined as contrast staining outside the stent contour extending to ≥20% of the stent diameter. The study population consisted of 3081 lesions (1998 patients) that were treated exclusively with sirolimus-eluting stents and were evaluated by follow-up angiography within 12 months after sirolimus-eluting stent implantation in a single center. Late acquired PSS was observed in 58 lesions (1.9%) in 49 patients (2.5%). Independent risk factors of PSS included chronic total occlusion, whereas negative risk factors for PSS were left circumflex coronary artery lesion and in-stent restenosis lesion. Stent fracture was more frequently observed in lesions with PSS than in lesions without PSS (43.1% versus 5.4%, P <0.0001). Excluding 269 lesions with target-lesion revascularization within 12 months, the study population for long-term follow-up consisted of 51 lesions (42 patients) with PSS and 2761 lesions (1751 patients) without PSS. Cumulative incidence of target-lesion revascularization and definite very late stent thrombosis at 3 years in the PSS group was higher than that in the non-PSS group (15.0% versus 6.5%, and 8.2% versus 0.2%, respectively). Conclusions—: Peri-stent contrast staining found within 12 months after sirolimus-eluting stent implantation appeared to be associated with subsequent target-lesion revascularization and very late stent thrombosis.

1 January 2009 in Diabetes
Verified
Journal Article
Open access
PDF file
PJPilar JiménEz-Quevedo
Pilar JiménEz-Quevedo
NSNobuaki Suzuki
Nobuaki Suzuki
CCCecilia Corros
Cecilia Corros
CFCruz Ferrer
Cruz Ferrer
DADominick J. Angiolillo
Dominick J. Angiolillo
MTManel Sabaté Tenas
Manel Sabaté Tenas
OBJECTIVE—The aim of this study was to determine the natural history of vascular remodeling of atherosclerotic plaques in patients with type 2 diabetes and the predictors of vessel shrinkage. RESEARCH DESIGN AND METHODS—In this serial intracoronary ultrasound (IVUS) study, 237 coronary segments from 45 patients enrolled in the DIABETES I, II, and III trials were included. Quantitative volumetric IVUS analyses (motorized pullbacks at 0.5 mm/s) were performed in the same coronary segment after the index procedure and at the 9-month follow-up. Nontreated mild lesions (angiographic stenosis <25%) with ≥0.5 mm plaque thickening and length of ≥5 mm assessed by IVUS were included. Vessel shrinkage was defined as a Δexternal elastic membrane area/Δplaque area < 0. Statistical adjustment by multiple segments and multiple lesions per patient was performed. RESULTS—Vessel shrinkage was identified in 37.1% of segments and was associated with a significant decrease in lumen area at 9 months (vessel shrinkage, 10 ± 4 mm2 vs. non–vessel shrinkage, 11 ± 4 mm2; P = 0.04). Independent predictors of vessel shrinkage were insulin requirements (odds ratio 4.6 [95% CI 1.40–15.10]; P = 0.01), glycated hemoglobin (1.5 [1.05–2.10]; P = 0.02), apolipoprotein B (0.96 [0.94–0.98]; P < 0.001), hypertension (3.7 [1.40–10.30]; P = 0.009), number of diseased vessels (5.6 [2.50–12.50]; P < 0.001), and prior revascularization (17.5 [6.50–46.90]; P < 0.001). CONCLUSIONS—This serial IVUS study suggests that progression of coronary artery disease in patients with type 2 diabetes may be mainly attributed to vessel shrinkage. Besides, vessel shrinkage is influenced by insulin requirements and metabolic control and is associated with more advanced coronary atherosclerosis.

1 August 2007 in American Heart Journal
Verified
Journal Article
Closed access
HFHideki Futamatsu
Hideki Futamatsu
NWNorbert Wilke
Norbert Wilke
CKChris Klassen
Chris Klassen
SSSteven Shoemaker
Steven Shoemaker
DADominick J. Angiolillo
Dominick J. Angiolillo
MCMarco A. Costa
Marco A. Costa